Neuromyelitis Optica Spectrum Disorder (NMOSD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Neuromyelitis Optica Spectrum Disorder Emerging Therapy and TPP Insights

Thelansis's "Neuromyelitis Optica Spectrum Disorder (NMOSD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system, most commonly driven by aquaporin-4 (AQP4-IgG) antibodies that attack astrocytes, causing recurrent inflammation of the optic nerves and spinal cord with permanent vision loss or paralysis after repeated relapses. Historically, treatment relied on off-label immunosuppressants, but the field changed with the approval of targeted biologics, including complement inhibitors, B-cell-depleting therapies, and IL-6 receptor blockers. These advances transformed NMOSD into a biomarker-defined disease with multiple mechanism-based treatment options. While newer agents offer convenient dosing and strong efficacy, observational real-world studies suggest that established, lower-cost immunosuppressive therapies remain effective for selected patients. For stakeholders, NMOSD illustrates how a single biomarker discovery can reshape both clinical care and therapeutic innovation.

Key Highlights

• In Germany, prevalent NMOSD cases are projected to increase from 3,363 in 2025 to 3,510 by 2035.
• NMOSD is a rare autoimmune disorder of the central nervous system characterized by recurrent attacks causing severe neurological disability.
• Despite recent therapeutic advances, preventing relapses remains a major treatment priority.
• Significant unmet need remains for therapies that provide durable relapse prevention and improved long-term outcomes.

Market Overview

• The Spain NMOSD market is projected to grow from $21M in 2025 to $52M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologics and complement inhibitors
• Improved diagnosis and growing disease awareness
• Future growth will depend on therapies capable of achieving sustained relapse prevention with favorable safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Amgen
• Alexion Pharmaceuticals, Inc.
• Hoffmann-La Roche
• Beijing Mabworks Biotech Co., Ltd.
• Bio-Thera Solutions
• CorestemChemon, Inc.